Whalesbook
Brooks Laboratories Limited has formally clarified to SEBI that it does not meet the criteria to be classified as a 'large corporate' (LC) for debt securities in the financial year ending March 31, 2026. The company reported outstanding borrowings of ₹1.19 crore as of the fiscal year-end, placing it well below SEBI’s ₹1,000 crore threshold for large corporations. This non-classification is further supported by its credit rating, CARE BB; Stable/CARE A4, which falls short of the required benchmarks.
The SEBI 'Large Corporate' framework aims to deepen the corporate bond market by mandating specific fundraising practices for eligible companies. These rules often require LCs to raise a significant portion of their debt through listed debt securities. By confirming its non-LC status for FY26, Brooks Laboratories gains exemption from these specific obligations, affording it greater flexibility in its fundraising strategies and compliance procedures.
Founded in 2002, Brooks Laboratories has a history of regulatory challenges. In 2015, SEBI imposed a five-year ban on the company and its top executives from accessing securities markets due to allegations of siphoning funds and concealing material information during its Initial Public Offering (IPO). More recently, the company's associate, Brooks Steriscience Limited (BSL), is undergoing a merger with OneSource Speciality Pharma Limited (OSPL), a transaction anticipated to enhance BLL's liquidity upon completion.
Despite the current compliance ease, Brooks Laboratories faces financial considerations. The company has substantial contingent liabilities amounting to ₹75.7 crore. Its credit rating of CARE BB; Stable/CARE A4 indicates a higher credit risk. Furthermore, as of March 31, 2025, its adjusted overall gearing stood at 3.09x, reflecting a moderate financial risk profile, partly due to guarantees provided for an associate entity.
Brooks Laboratories is not alone in seeking this exemption. Other companies, such as Welterman International, have also recently confirmed they do not meet SEBI's 'Large Corporate' debt issuance criteria for FY26, citing similar reasons of not meeting borrowing thresholds or credit rating requirements.
Investors are advised to monitor Brooks Laboratories' future quarterly and annual reports for any significant changes in borrowing levels. Updates on its credit rating from CARE Ratings will be important. The progress and completion of the merger involving Brooks Steriscience Limited and its impact on BLL's liquidity will also be a key focus. Additionally, any future strategic debt issuance plans by the company and their compliance with evolving SEBI norms will be closely observed.